Inotiv, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert W. Leasure Jr.
- Full Time Employees
- 1,977
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 2701 Kent Avenue West Lafayette IN United States of America 47906-1382
- IPO Date
- Nov 25, 1997
- CIK
- 0000720154
- Website
- inotivco.com
- Similar Companies
- Business
- Inotiv, Inc. (NOTV) is a leading contract research organization that provides nonclinical and analytical drug discovery and development services, research models, and related products to the pharmaceutical, biotechnology, chemical, and medical device industries. The company operates through two primary segments: Discovery and Safety Assessment (DSA), which offers in vitro and in vivo studies, pharmacology, toxicology, drug metabolism and pharmacokinetics (DMPK), bioanalytical services including LC-MS/MS and immunoassays, genetic toxicology, histopathology, biotherapeutics, medical device testing, and safety pharmacology; and Research Models and Services (RMS), which provides genetically modified and transgenic research models such as rodents, non-human primates (NHP) products and services, diets, bedding, bioproducts, surgical and interventional procedures, and model characterization. Inotiv manufactures and sells analytical instruments and software under the BASi product line, including in vivo sampling systems, physiology monitoring tools, liquid chromatography, and electrochemistry platforms for pharmaceutical companies, universities, government research centers, and medical institutions. The company serves clients in the United States, the Netherlands, rest of North America, Europe, the Pacific Rim, and internationally. Founded in 1974 and headquartered in West Lafayette, Indiana, Inotiv supports target markets including pharmaceutical and biotechnology firms, contract research organizations, academic institutions, and government entities through end-to-end preclinical solutions that accelerate drug development, enhance data quality, and reduce costs. In recent years, Inotiv has pursued strategic optimization and integration following a period of aggressive growth through 14 acquisitions between 2018 and 2023, including Bioanalytical Research Corporation in 2018 for large molecule bioanalysis, Plato BioPharma in 2019 for cardiovascular, renal, and pulmonary models, Bolder BioPATH and HistoTox Labs in 2021 for pathology and pharmacology expansion, CiToxLAB for toxicology in 2021, and Envigo in 2021 for research models. The company divested its RMS business in 2022 to Envigo RMS Holding Corp. for $53.5 million to simplify operations and focus on higher-growth DSA segments; appointed Robert Leasure Jr. as CEO in 2023 to address financial challenges; and completed RMS site and transportation optimizations in fiscal 2025, yielding $6-7 million in annual cost savings, alongside DSA third-party spend reductions from 3.4% in 2022 to 2.0% in 2025, IT system consolidation from 249 to 164 platforms, U.K. facility expansions at Hillcrest, and enhanced compliance programs including a Chief Compliance Officer and Nationwide Compliance Plan post a $7.6 million settlement. These initiatives drove fiscal 2025 year-to-date revenue growth of 4.0% to $374.9 million through June 30, with Q3 revenue up 23.5% to $130.7 million, fueled by RMS NHP services and DSA toxicology, biotherapeutics, and medical devices, and preliminary Q4 revenue projected at $137.5-138.5 million for full-year revenue of approximately $515 million. Inotiv targets long-term annual revenue of $590-610 million and Adjusted EBITDA margins of 16.5-18.5% through organic growth in discovery, genetic toxicology, NHP, and opportunistic mergers and acquisitions, with RMS site optimizations completing by Q2 fiscal 2026.
Inotiv Reaches Agreement to Strengthen Capital Structure and Position Company for Future Growth
Inotiv Provides Notice Regarding Cybersecurity Incident
Inotiv, Inc. (NOTV) Q1 2026 Earnings Call Transcript
Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update
Inotiv, Inc. to Report Fiscal 2026 First Quarter Financial Results and Host Conference Call on Monday, February 9, 2026
Ernexa Therapeutics (NASDAQ:ERNA) vs. Inotiv (NASDAQ:NOTV) Critical Review
Inotiv Leverages LifeNet Health Proprietary Platform to Advance New Approach Methodologies in Translational Drug Discovery
Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities
Inotiv, Inc. (NOTV) Q4 2025 Earnings Call Transcript
Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update
Inotiv Ranked Number 182nd Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500™
Inotiv, Inc. to Report Fiscal 2025 Fourth Quarter and Full Year Financial Results and Host Conference Call on Wednesday, December 3, 2025
Inotiv, Inc. Announces Preliminary Fiscal 2025 Fourth Quarter and Full Year Results
Halper Sadeh LLC Encourages Inotiv, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Inotiv, Inc. to Participate in Three Investor Conferences in September 2025
Inotiv, Inc. (NOTV) Q3 2025 Earnings Call Transcript
CORRECTING and REPLACING - Inotiv Reports Third Quarter Financial Results for Fiscal 2025 and Provides Business Update
Inotiv, Inc. (NOTV) Reports Q3 Loss, Tops Revenue Estimates
Inotiv Reports Third Quarter Financial Results for Fiscal 2025 and Provides Business Update
Inotiv, Inc. to Report Fiscal 2025 Third Quarter Financial Results and Host Conference Call on Wednesday, August 6, 2025